Device for treating pulmonary fibrosis by dropping human mesenchymal stem cells into airway

A technology of mesenchymal stem cells and fibrosis, applied in the field of medicine and biology, can solve the problems of high price, reduced utilization of input stem cells, and no substantial improvement

Pending Publication Date: 2021-12-31
SHANGHAI LIFE SCI & TECH CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Clinically, most patients seeking treatment for breathing problems are not in the early stage, but have developed pulmonary fibrosis, and the existing clinical drug effects can only relieve the patient's symptoms without substantial improvement, and The price is expensive, so it is necessary to provide new and effective treatment methods for pulmonary fibrosis and precise drug delivery routes, so as to not only delay the process of fibrosis, but more importantly, reverse the state of pulmonary fibrosis and truly solve the problem of fibrosis. The status quo of the incurable disease
At present, the clinical use of stem cells reaches the whole body through intravenous injection, which is not a precise drug delivery method, and also reduces the utilization rate of input stem cells, making it impossible to fully utilize the advantages of stem cells in treating diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Device for treating pulmonary fibrosis by dropping human mesenchymal stem cells into airway
  • Device for treating pulmonary fibrosis by dropping human mesenchymal stem cells into airway
  • Device for treating pulmonary fibrosis by dropping human mesenchymal stem cells into airway

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0124] The establishment of embodiment 1 pulmonary fibrosis animal model

[0125] 1.1 Experimental animals and feeding conditions

[0126] The experimental animals used in the experiment are Sprague-Dawley rats (SD rats), with a body weight of about 245-350g, raised in transparent PC cages with a size of 45×24×20cm, and illuminated for 12 hours a day (from 7:30 in the morning to in the afternoon). At 7:30), the ambient temperature is constant temperature and air-conditioning (22±2°C) and the feed (Laboratory Animal Diets MF18) and drinking water are adequately supplied, and the litter is replaced once a week.

[0127] 1.2 Establishment of animal model of left lung fibrosis

[0128] The animal was anesthetized by intraperitoneal injection of chloral hydrate (about 350mg / kg, 100mg / mL), and then fixed on a rat holder placed at 45°. Using a small animal anesthesia laryngoscope, the base of the tongue was pressed to expose the glottis. Connect the syringe that draws 0.3mL of the ...

Embodiment 2

[0190] The distribution of cell drug in the non-invasive way of dripping in embodiment 2

[0191] 2.1. Intratracheal instillation

[0192] Intratracheal drop administration method of rats: Anesthetize the animal and fix it on a fixture placed at 45 degrees, use ophthalmic forceps to pull out the tongue, and use a small animal anesthesia laryngoscope to press the base of the animal's tongue to expose the glottis, and extract Gently insert the atomizing needle (blunt) of an appropriate amount of drug syringe into the trachea to a depth of about 1.5cm, then push the syringe to send the drug liquid through the airway into the lungs, quickly pull out the needle, remove the animal from the holder, and turn the head toward the lungs. Up and down, rotate left and right for about 1 minute, so that the drug can be distributed in each lung lobe as much as possible.

[0193] At predetermined time points, PET / CT scans were performed on the animals to assess the distribution of cells in th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a device for treating pulmonary fibrosis by dropping human mesenchymal stem cells into an airway. Specifically, the invention provides a method and device for treating pulmonary fibrosis by dropping human mesenchymal stem cells into the airway. The device comprises: (a) a first container filled with a first pharmaceutical composition, wherein the first pharmaceutical composition contains the human mesenchymal stem cells and a pharmaceutically acceptable carrier; (b) a dilator for dilating the airway, wherein the dilator is used for dilating the airway of a patient; (c) a dropper, wherein the dropper is used for dropping the first pharmaceutical composition into the airway of the patient, the dropper is configured such that the distal end of the dropper can be inserted into the dilated airway and the first pharmaceutical composition is dropped into the airway through the distal end; and a connecting pipe (d) which is used for connecting the first container with the dropper to form a flow channel for flowing the first pharmaceutical composition, wherein the first pharmaceutical composition is a liquid preparation, and has no irritation to the airway and lungs. Different from a method of administration through bronchial injection by cutting a neck, the human mesenchymal stem cells in the device disclosed by the invention are administered in an intra-airway dropping manner, and the method belongs to noninvasive administration methods.

Description

technical field [0001] The invention belongs to the field of medical biology, and in particular relates to the treatment of pulmonary fibrosis by dripping human mesenchymal stem cells in the airway. Background technique [0002] Pulmonary fibrosis is the end-stage change of a large class of lung diseases characterized by fibroblast proliferation and accumulation of a large amount of extracellular matrix, accompanied by inflammatory damage and tissue structure destruction, that is, normal alveolar tissue is damaged and undergoes abnormal repair to lead to structural changes. Abnormal (scarring). The cause of most patients with pulmonary fibrosis is unknown (idiopathic). The most common type of disease with pulmonary fibrosis as the main manifestation is idiopathic pulmonary fibrosis (IPF), which is a disease that can lead to progressive lung function. Loss of severe interstitial lung disease. Pulmonary fibrosis seriously affects the respiratory function of the human body, m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61M31/00A61K9/00A61K35/28A61P11/00
CPCA61M31/002A61K35/28A61K9/007A61P11/00A61M2202/09A61M2202/04A61M2210/1032A61M2210/1039
Inventor 高宏林春媛蒋蕊
Owner SHANGHAI LIFE SCI & TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap